Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 9, 905-916
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasbekar, N.
Right arrow Articles by Acharya, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasbekar, N.
Right arrow Articles by Acharya, P. S.

Clinical Review

Telithromycin: The first ketolide for the treatment of respiratory infections

Nishaminy Kasbekar and Pinak S. Acharya

NISHAMINY KASBEKAR, PHARM.D., is Clinical Specialist, Infectious Diseases, Department of Pharmacy, University of Pennsylvania Medical Center (UPMC)—Presbyterian, Philadelphia. PINAK S. ACHARYA, M.D., is Clinical Instructor, Division of Pulmonary, Allergy and Critical Care Medicine, UPMC.

Address correspondence to Dr. Kasbekar at the Department of Pharmacy, University of Pennsylvania Medical Center—Presbyterian, 51 North 39th Street, Philadelphia, PA 19104 (nishaminy.kasbekar{at}uphs.upenn.edu).


Purpose. The pharmacology, mechanisms of resistance, in vitro activity, clinical efficacy, pharmacokinetics, indications, adverse effects, dosage and administration, and place in therapy of telithromycin in the treatment of respiratory infections are reviewed.

Summary. Telithromycin is the first ketolide to be approved in the United States for use against common respiratory pathogens. The unique structure of telithromycin allows for enhanced binding to bacterial ribosomal RNA, thereby blocking protein synthesis. Its spectrum of activity includes pathogens implicated in common respiratory infections (Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumonia, and Chlamydia pneumoniae) and multidrug-resistant isolates of pneumococcus. Clinical efficacy has been documented in several multicenter, comparative trials for the treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis, acute maxillary sinusitis, and pharyngitis tonsillitis. Although studies have demonstrated that the clinical efficacy of telithromycin is comparable to macrolides, telithromycin is unique in that it provides activity against penicillin- and macrolide-resistant respiratory pathogens. The recommended dosage of telithromycin is 800 mg p.o. once daily. The most common adverse events resulting from telithromycin use include diarrhea, nausea, headache, dizziness, vomiting, loose stools, dysgeusia, and dyspepsia. The drug’s adverse-event profile is comparable to that of similar agents. Telithromycin is a strong inhibitor of cytochrome P-450 isoenzyme 3A4; therefore, it can affect the efficacy and toxicity profile of medications that are metabolized by this isoenzyme.

Conclusion. Telithromycin is a reasonable addition to the current treatment options for upper-respiratory-tract infections. Its use should be restricted to infections caused by penicillin- and macrolide-resistant pathogens.

Index terms: Dosage; Drug administration; Drug interactions; Ketolides; Mechanism of action; Pharmacokinetics; Resistance; Respiratory-tract infections; Spectrum microbial; Telithromycin; Toxicity

 



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
S. Bolesta and B. P. Roslund
Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review
Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 37 - 41.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. Caramori, A. Papi, A. Mutgi, J. Hammersley, Y. Kuramochi, T. Morita, R. Osawa, R. Andraws, S. L. Johnston, R. B. Nieman, et al.
Telithromycin in acute exacerbations of asthma.
N. Engl. J. Med., July 6, 2006; 355(1): 96 - 97.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Yamaguchi, Y. L. Zhao, M. Nadai, H. Yoshizumi, X. Cen, S. Torita, K. Takagi, K. Takagi, and T. Hasegawa
Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Telithromycin Transport
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 80 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
D. N. Fish
Telithromycin: Do we really need this antimicrobial?
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 901 - 901.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.
Advertisement